Screening and prevention of toxic optic neuropathies due to anti-mycobacterium therapies : proposal of recommendations
Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved..
While treatment of pulmonary infections by Mycobacterium tuberculosis is currently only rarely the cause of iatrogenic complications, treatment of atypical mycobacterial infections often requires prolonged treatment duration, which can lead to toxic optic neuropathies. This review summarizes the indications for such prolonged treatment and risk factors for toxic optic neuropathies when using ethambutol, isoniazid and/or linezolid and proposes customized screening recommendations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Journal francais d'ophtalmologie - 45(2022), 5 vom: 09. Mai, Seite 495-503 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Dépistage et prévention des neuropathies optiques toxiques aux anti-mycobactériens : proposition de recommandations |
|---|
| Beteiligte Personen: |
Orssaud, C [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.05.2022 Date Revised 17.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jfo.2021.08.016 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339595574 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339595574 | ||
| 003 | DE-627 | ||
| 005 | 20231226003239.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.jfo.2021.08.016 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1131.xml |
| 035 | |a (DE-627)NLM339595574 | ||
| 035 | |a (NLM)35430117 | ||
| 035 | |a (PII)S0181-5512(21)00594-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Orssaud, C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Screening and prevention of toxic optic neuropathies due to anti-mycobacterium therapies |b proposal of recommendations |
| 246 | 3 | 3 | |a Dépistage et prévention des neuropathies optiques toxiques aux anti-mycobactériens : proposition de recommandations |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.05.2022 | ||
| 500 | |a Date Revised 17.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved. | ||
| 520 | |a While treatment of pulmonary infections by Mycobacterium tuberculosis is currently only rarely the cause of iatrogenic complications, treatment of atypical mycobacterial infections often requires prolonged treatment duration, which can lead to toxic optic neuropathies. This review summarizes the indications for such prolonged treatment and risk factors for toxic optic neuropathies when using ethambutol, isoniazid and/or linezolid and proposes customized screening recommendations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Atypical mycobacteria | |
| 650 | 4 | |a Dépistage | |
| 650 | 4 | |a Ethambutol | |
| 650 | 4 | |a Isoniazid | |
| 650 | 4 | |a Isoniazide | |
| 650 | 4 | |a Linezolid | |
| 650 | 4 | |a Linézolide | |
| 650 | 4 | |a Mycobactérie atypique | |
| 650 | 4 | |a Neuropathie optique toxique | |
| 650 | 4 | |a OCT | |
| 650 | 4 | |a Screening | |
| 650 | 4 | |a Toxic optic neuropathy | |
| 650 | 4 | |a Tuberculose | |
| 650 | 4 | |a Tuberculosis | |
| 650 | 4 | |a Éthambutol | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 650 | 7 | |a Ethambutol |2 NLM | |
| 650 | 7 | |a 8G167061QZ |2 NLM | |
| 650 | 7 | |a Linezolid |2 NLM | |
| 650 | 7 | |a ISQ9I6J12J |2 NLM | |
| 650 | 7 | |a Isoniazid |2 NLM | |
| 650 | 7 | |a V83O1VOZ8L |2 NLM | |
| 700 | 1 | |a Nguyen, D T |e verfasserin |4 aut | |
| 700 | 1 | |a Rouzaud, C |e verfasserin |4 aut | |
| 700 | 1 | |a Pavie, J |e verfasserin |4 aut | |
| 700 | 1 | |a Pinot, J |e verfasserin |4 aut | |
| 700 | 1 | |a Lortholary, O |e verfasserin |4 aut | |
| 700 | 1 | |a Bremond-Gignac, D |e verfasserin |4 aut | |
| 700 | 1 | |a Robert, M P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal francais d'ophtalmologie |d 1993 |g 45(2022), 5 vom: 09. Mai, Seite 495-503 |w (DE-627)NLM000357944 |x 1773-0597 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2022 |g number:5 |g day:09 |g month:05 |g pages:495-503 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jfo.2021.08.016 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2022 |e 5 |b 09 |c 05 |h 495-503 | ||